Focused On-demand Library for TATA-binding protein-associated factor 172

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

O14981

UPID:

BTAF1_HUMAN

Alternative names:

ATP-dependent helicase BTAF1; B-TFIID transcription factor-associated 170 kDa subunit; TAF(II)170; TBP-associated factor 172

Alternative UPACC:

O14981; B4E0W6; O43578

Background:

TATA-binding protein-associated factor 172, also known as ATP-dependent helicase BTAF1, plays a crucial role in regulating transcription in association with TATA binding protein (TBP). It uniquely removes TBP from the TATA box in an ATP-dependent manner, highlighting its significance in the transcription initiation process. Alternative names include B-TFIID transcription factor-associated 170 kDa subunit, TAF(II)170, and TBP-associated factor 172.

Therapeutic significance:

Understanding the role of TATA-binding protein-associated factor 172 could open doors to potential therapeutic strategies. Its pivotal function in transcription regulation suggests that modulating its activity could influence gene expression patterns involved in various diseases.